Iantrek, a pioneer in bio-interventional ophthalmic surgery (BIOS), announced the close of a $42 million Series C financing round, which will fund the U.S. commercial launch of AlloFlo Uveo, a first-of-its-kind surgical solution targeting the uveoscleral pathway, as well as broader pipeline expansion.

The Series C was led by U.S. Venture Partners (USVP), joined by aMoon Fund, along with existing investors Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures.